(Cilofexor + firsocostat) is under clinical development by Gilead Sciences and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Cilofexor + firsocostat)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Cilofexor + firsocostat) overview
A fixed dose combination of cilofexor and firsocostat is under development for the treatment of compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). It is administered through oral route as tablet. cilofexor acts by targeting farnesoid X receptor (FXR) and firsocostat acts by targeting acetyl CoA carboxylase (ACC).
Gilead Sciences overview
Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It carries out the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, cancer, and human immunodeficiency virus (HIV) infection. Gilead markets its products through commercial teams, third-party distributors and corporate partners. Gilead’s commercial teams promote its products through direct field contact with physicians, hospitals, clinics and other healthcare providers. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East, and Africa. Gilead is headquartered in Foster City, California, the US.
For a complete picture of (Cilofexor + firsocostat)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
